# OnCo record rejuv-frontier-rapamycin-ageing (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/rejuv-frontier-rapamycin-ageing/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "rejuv-frontier-rapamycin-ageing" ;
  schema:name "Rapamycin and mTOR inhibition for ageing"@en ;
  schema:description "Rapamycin extends life in every species it has been properly tested in, which is why people take it off-label. In humans there are two randomised results worth knowing: a related drug improved the flu vaccine response in older people by about a fifth, and a year of low-dose rapamycin in healthy adults did not change its primary endpoint. That is the whole of it."@en ;
  schema:url <https://onco.cc/technologies/rejuv-frontier-rapamycin-ageing/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Sirolimus> ;
  schema:citation <https://doi.org/10.1126/scitranslmed.3009892>, <https://doi.org/10.18632/aging.206235> ;
  onco:status "phase-2" ;
  onco:tag "rejuvenation", "survivorship", "evidence:insufficient", "repurposing" ;
  onco:related <https://onco.cc/technologies/rejuv-frontier-immune-reconstitution/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/survivorship-care-plan/> ;
  onco:drugs <https://onco.cc/drugs/sirolimus/>, <https://onco.cc/drugs/everolimus/> ;
  onco:terms <https://onco.cc/terms/late-effects/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/> .